Matthew Porteus, Kamau Therapeutics co-founder and acting CEO

Graphite founder takes drug to re­cent­ly-launched Ka­mau Ther­a­peu­tics for a sec­ond chance: #ASH23

SAN DIEGO — Af­ter Graphite Bio’s im­plo­sion, Matthew Por­teus wants to do things dif­fer­ent­ly.

The Stan­ford re­searcher’s stint at the biotech end­ed with Graphite

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.